The Agents Intervening against Delirium in the Intensive Care Unit Trial (AID-ICU trial): A detailed statistical analysis plan

Nina Andersen-Ranberg*, Lone M. Poulsen, Anders Perner, Jørn Wetterslev, Ole Mathiesen, Camilla B. Mortensen, Stine Estrup, Bjørn H. Ebdrup, Johanna Hästbacka, Giuseppe Citerio, Jesus Caballero, Matthew P.G. Morgan, Marie Oxenbøll-Collet, Sven Olaf Weber, Anne Sofie Andreasen, Morten H. Bestle, Helle B.S. Pedersen, Louise G. Nielsen, Bülent Uslu, Troels B. JensenCarsten Thee, Nilanjan Dey, Theis Lange

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

154 Downloads (Pure)


Background: The AID-ICU trial aims to assess the benefits and harms of haloperidol for the treatment of delirium in acutely admitted, adult intensive care unit (ICU) patients. This paper describes the detailed statistical analysis plan for the primary publication of results from the AID-ICU trial. Methods: The AID-ICU trial is an investigator-initiated, pragmatic, international, multicentre, randomized, blinded, parallel-group trial allocating 1000 adult ICU patients with manifest delirium 1:1 to haloperidol or placebo. The primary outcome measure is days alive and out of hospital within 90 days post-randomization. Secondary outcome measures are days alive without delirium or coma, serious adverse reactions (SARs) to haloperidol, use of escape medicine, days alive without mechanical ventilation, and mortality, health-related quality-of-life measures and cognitive function 1-year post-randomization. Statistical analysis will be conducted in accordance with the current pre-specified statistical analysis plan. One formal interim analysis will be performed. The primary outcome will be adjusted for stratification variables (site and delirium motor subtype) and compared between treatment groups using a likelihood ratio test described by Jensen et al A secondary analysis will be conducted with additional adjustment of the primary outcome for prognostic variables at baseline. The primary conclusion of the trial will be based on the intention-to-treat analysis of the primary outcome adjusted for stratification variables. Conclusion: The AID-ICU trial will provide important, high-quality data on the benefits and harms of treatment with haloperidol in acutely admitted, adult patients with manifest delirium in the ICU.

Original languageEnglish
JournalActa Anaesthesiologica Scandinavica
Issue number9
Pages (from-to)1357-1364
Publication statusPublished - 1. Oct 2020


Dive into the research topics of 'The Agents Intervening against Delirium in the Intensive Care Unit Trial (AID-ICU trial): A detailed statistical analysis plan'. Together they form a unique fingerprint.

Cite this